Back to top
more

Cellebrite DI Ltd. (CLBT)

(Delayed Data from NSDQ)

$13.57 USD

13.57
988,574

-0.25 (-1.81%)

Updated Aug 8, 2025 03:59 PM ET

After-Market: $13.65 +0.08 (0.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Internet - Software

Zacks News

Zacks Equity Research

StoneCo Ltd. (STNE) Beats Q2 Earnings and Revenue Estimates

StoneCo (STNE) delivered earnings and revenue surprises of +8.33% and +2.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Match Group (MTCH) Lags Q2 Earnings Estimates

Match Group (MTCH) delivered earnings and revenue surprises of -11.11% and +1.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Tops Q1 Earnings Estimates

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 11.11% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arteris, Inc. (AIP) Reports Q1 Loss, Tops Revenue Estimates

Arteris (AIP) delivered earnings and revenue surprises of 18.18% and 3.98%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CCC Intelligent Solutions Holdings Inc. (CCCS) Meets Q1 Earnings Estimates

CCC Intelligent Solutions (CCCS) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SMGZY or CLBT: Which Is the Better Value Stock Right Now?

SMGZY vs. CLBT: Which Stock Is the Better Value Option?

Arghyadeep Bose headshot

Priority Technology Skyrockets 227% in a Year: Should You Buy it?

Given the surge in PRTH shares, we evaluate its current position to determine whether investors should jump on the stock's year-old rally.

Zacks Equity Research

After Plunging -17.61% in 4 Weeks, Here's Why the Trend Might Reverse for Cellebrite DI Ltd. (CLBT)

Cellebrite DI Ltd. (CLBT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Q4 Earnings Meet Estimates

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AppLovin (APP) Q4 Earnings and Revenues Top Estimates

AppLovin (APP) delivered earnings and revenue surprises of 29.10% and 8.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cellebrite to Report Q4 Earnings: Here's What You Should Know

The surge in subscription filters is likely to have benefited CLBT's top line in the fourth quarter of 2024.

Zacks Equity Research

NU or CLBT: Which Is the Better Value Stock Right Now?

NU vs. CLBT: Which Stock Is the Better Value Option?

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Tops Q3 Earnings and Revenue Estimates

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 27.27% and 4.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Distribution Solutions Group (DSGR) Q3 Earnings and Revenues Lag Estimates

Distribution Solutions (DSGR) delivered earnings and revenue surprises of -7.50% and 0.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Cellebrite DI Ltd. (CLBT) a New Strong Buy Stock

Cellebrite DI Ltd. (CLBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Here's Why You Should Retain ENV Stock in Your Portfolio for Now

Consistent growth in recurring revenues, and improving efficiency and competitiveness are benefiting Envestnet's performance.

Zacks Equity Research

Trane Technologies plc (TT) Hits Fresh High: Is There Still Room to Run?

Trane Technologies (TT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Hit a 52 Week High, Can the Run Continue?

Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?

Here is how Cellebrite DI Ltd. (CLBT) and Nexxen International Ltd. Sponsored ADR (NEXN) have performed compared to their sector so far this year.

Zacks Equity Research

Is Exponent (EXPO) Stock Outpacing Its Business Services Peers This Year?

Here is how Exponent (EXPO) and Cellebrite DI Ltd. (CLBT) have performed compared to their sector so far this year.

Zacks Equity Research

Are Business Services Stocks Lagging Adyen (ADYEY) This Year?

Here is how Adyen N.V. Unsponsored ADR (ADYEY) and Cellebrite DI Ltd. (CLBT) have performed compared to their sector so far this year.

Zacks Equity Research

Why Cellebrite DI Ltd. (CLBT) Might be Well Poised for a Surge

Cellebrite DI Ltd. (CLBT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?

Here is how Cellebrite DI Ltd. (CLBT) and Genpact (G) have performed compared to their sector so far this year.

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Soars to 52-Week High, Time to Cash Out?

Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Cellebrite DI Ltd. (CLBT) Tops Q2 Earnings and Revenue Estimates

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 25% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?